How to distinguish between the neuroleptic-induced deficit syndrome, depression and disease-related negative symptoms in schizophrenia

被引:43
作者
Barnes, TRE
McPhillips, MA
机构
[1] Charing Cross and Westminster Medical School, London, W6 8RP, St Dunstan’s Road
关键词
schizophrenia; depressive features; negative symptoms; dysphoria; subjective experience; compliance; neuroleptics;
D O I
10.1097/00004850-199509000-00015
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A major challenge in the clinical assessment of schizophrenia is the differentiation between depressive features, negative symptoms and neuroleptic side effects, including the adverse subjective experiences associated with this medication, The problems include the degree of symptom overlap, and the lack of precise operational definitions, particularly for negative symptoms and the putative, neuroleptic-induced deficit syndrome. The diagnostic process is further confounded by the need to discriminate between primary negative symptoms as persistent, enduring deficits, and social and emotional withdrawal secondary to positive symptoms, or related to depressive features or drug effects such as sedation and the bradykinesia component of parkinsonism. To distinguish between these elements is likely to require careful observation of patients with schizophrenia, over time, by trained raters using appropriate rating scales for depression and negative symptoms that are sensitive to change, Ratings of patients' subjective experiences regarding mood and awareness of behavioural and cognitive deficits should also be included. The associations between the subjective data and the objective ratings of depression, negative symptoms and drug side effects may help with clinical discrimination in these areas of dysfunction and with the refinement of their phenomenological descriptions.
引用
收藏
页码:115 / 121
页数:7
相关论文
共 63 条
[1]   ASSESSING DEPRESSION IN SCHIZOPHRENIA - THE CALGARY DEPRESSION SCALE [J].
ADDINGTON, D ;
ADDINGTON, J ;
MATICKATYNDALE, E .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 :39-44
[2]   SPECIFICITY OF THE CALGARY-DEPRESSION-SCALE FOR SCHIZOPHRENICS [J].
ADDINGTON, D ;
ADDINGTON, J ;
MATICKATYNDALE, E .
SCHIZOPHRENIA RESEARCH, 1994, 11 (03) :239-244
[3]  
Andreasen N C, 1990, Mod Probl Pharmacopsychiatry, V24, P1
[4]  
ANDREASEN N C, 1989, British Journal of Psychiatry, V155, P49
[5]  
ASBERG M, 1978, ACTA PSYCHIATRICA S, V277, P5
[6]   SUBJECTIVE RESPONSE TO NEUROLEPTICS IN SCHIZOPHRENIA [J].
AWAD, AG .
SCHIZOPHRENIA BULLETIN, 1993, 19 (03) :609-618
[7]  
Barnes T R, 1990, Mod Probl Pharmacopsychiatry, V24, P43
[8]  
Barnes T. R. E., 1994, CURRENT OPINION PSYC, V7, P35
[9]   THE NATURE AND PREVALENCE OF DEPRESSION IN CHRONIC-SCHIZOPHRENIC INPATIENTS [J].
BARNES, TRE ;
CURSON, DA ;
LIDDLE, PF ;
PATEL, M .
BRITISH JOURNAL OF PSYCHIATRY, 1989, 154 :486-491
[10]  
BARNES TRE, 1994, ASSESSMENT PSYCHOSES, P51